Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
Douglass
J A
JA
Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital and Monash University, Melbourne, Victoria, Australia. J.Douglass@alfred.org.au
Carroll
K
K
Voskamp
A
A
Bourke
P
P
Wei
A
A
O'Hehir
R E
RE
D000707:Anaphylaxis / Q000209:etiology / Q000517:prevention & control; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology; D034721:Mastocytosis, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D000069444:Omalizumab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab